ACCELERATING THERAPEUTICS FOR PLEXIFORM AND CUTANEOUS NEUROFIBROMAS

Read more

TWO NEW CLINICIAN-SCIENTISTS CHOSEN FOR NEUROFIBROMATOSIS AWARD, RESEARCH SUPPORT

NTAP is pleased to announce the selection of Dr. Ina Ly and Dr. Shruti Garg as the 2018 Francis Collins Scholars. The next call for applicants will take place in December 2018; applications due March 2019.

News

July 10, 2018: Cutaneous Neurofibromas Initiative Outlines Current Biology and Paths Forward for Clinicians and Scientists: NTAP organized a summit designed to define the state of the field, to prioritize research questions, and to create a community of thinkers invested in developing effective cNF therapeutics.  The fruit of the cNF summit is a ‘research roadmap’ for targeting cNF that is captured in five manuscripts published in Neurology®... read more 

Partner with NTAP

NTAP partners with key stakeholders in plexiform and cutaneous neurofibroma therapeutic research to ensure efforts are synergistic and have the greatest possible impact.

————————————————————————————————————————————————–

NTAP Announces the Annual 2018 Children’s Tumor Foundation NF Conference/18th European Neurofibromatosis Meeting

What We Do

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is focused exclusively on improving treatment options for people living with Neurofibromatosis type 1-related plexiform neurofibromas. With the goal of therapeutics always in mind, initiatives span research that probes the basic aspects of tumorgenesis through clinical investigations of drugs that have the highest likelihood of having a positive impact for patients. NTAP’s approach is defined by (1) intense collaboration both within and outside of the neurofibromatosis research community and (2) ongoing critical assessment of the existing needs and opportunities for developing effective plexiform neurofibroma therapeutics.